Sporadic Inclusion Body Myositis Natural History Study

NCT ID: NCT05046821

Last Updated: 2024-04-09

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-10-11
• Study Completion Date: 2026-01-31

Brief Summary

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

Detailed Description

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants with sporadic IBM, diagnosed according to established criteria. Participants will require an routine serum sample via blood draw to evaluate for NT5c1A antibody status. This testing will be performed at Washington University School of Medicine in the Neuromuscular Laboratory. Investigators will be blinded to antibody status. A subset of participants (40) will undergo a muscle biopsy at the Baseline visit.

Aim 1. To determine for the first time whether NT5c1A antibodies mediate disease progression over a two-year interval in patients with sIBM.

We will perform a prospective, non-interventional, observational study on patients with sIBM with follow up and evaluations every 6 months over a two-year time frame. Primary analyses are: 1) the rates of disease progression and severity as measured by rates of decline in IBM Functional Rating Scale (IBMFRS) score and Timed Get Up and Go (TUG); 2) the presence or absence of serum antibodies to NT5c1A; and 3) the presence and frequency of variant T-cells in the serum and skeletal muscle.

Aim 2. To perform a detailed morphological, histochemical and immunohistochemical analysis of fresh muscle biopsy specimens obtained from a subset of patients with sIBM.

Aim 3. To characterize the distribution of "immunosenescent" lymphocytes in circulating blood from patients with sIBM.

Aim 4. To quantify the decline in the respiratory function of sIBM patients.

Conditions

Sporadic Inclusion Body Myositis; Inclusion Body Myositis

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. Ages 40 years and older

2. Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body myositis (sIBM)

3. Disease onset is within the past 10 years of the time of Baseline visit

4. Able to participate and comply with study related procedures

5. Able to provide written consent

Exclusion Criteria

1. Current or very recent use (within last 6 months of the Baseline visit) of immunomodulation or immunosuppression therapy.

2. Current or very recent use (within last 90 days of the Baseline visit) of an investigational medication or therapy.

3. Co-existing significant medical or surgical conditions that, in the opinion of the investigator, will influence study participation or alter natural history.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

Sponsor Role: collaborator

University of California, Irvine

OTHER

Sponsor Role: lead

Responsible Party

Tahseen Mozaffar

Professor of Neurology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tahseen Mozaffar, MD FAAN, FANA

Role: PRINCIPAL_INVESTIGATOR

University of California, Irvine

Locations

University of California, Los Angeles

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

University of Colorado

Aurora, Colorado, United States

University of Miami

Miami, Florida, United States

Kansas University Medical Center

Fairway, Kansas, United States

Johns Hopkins University

Baltimore, Maryland, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Washington University in St. Louis

St Louis, Missouri, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Nerve and Muscle Center of Texas

Houston, Texas, United States

University of Washington

Seattle, Washington, United States

Countries

United States

Other Identifiers

R01AR078340-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

20216779

Identifier Type: -

Identifier Source: org_study_id